drugset / Trial / NCT00743288
Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving melphalan together with panobinostat may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of melphalan when given together with panobinostat in treating patients with recurrent multiple myeloma.
Timeline
- Start
- 2008-07
- Primary completion
- 2012-11
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Melphalan | Small molecule | 0.05 mg/kg | Oral |
| Subject | Melphalan | Small molecule | 0.1 mg/kg | Oral |
| Subject | Panobinostat | Small molecule | 10 mg | Oral |
| Subject | Panobinostat | Small molecule | 15 mg | Oral |
| Subject | Panobinostat | Small molecule | 20 mg | Oral |